NOVOCURE LIMITED

(NVCR)
  Report
Real-time Estimate Cboe BZX  -  05/18 10:22:32 am EDT
71.66 USD   -0.04%
05/16NovoCure's Shares Rise After HC Wainwright Initiates Coverage at Buy
MT
05/16HC Wainwright Initiates NovoCure at Buy With $115 Price Target
MT
05/13Piper Sandler Adjusts NovoCure's Price Target to $100 From $125, Reiterates Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NovoCure Reports Preliminary Q4 Net Revenue of $133.2 Million

01/10/2022 | 07:32am EDT


© MT Newswires 2022
All news about NOVOCURE LIMITED
05/16NovoCure's Shares Rise After HC Wainwright Initiates Coverage at Buy
MT
05/16HC Wainwright Initiates NovoCure at Buy With $115 Price Target
MT
05/13Piper Sandler Adjusts NovoCure's Price Target to $100 From $125, Reiterates Overweight ..
MT
04/28NovoCure's Q1 Net Loss Flat, Revenue Rises
MT
04/28TRANSCRIPT : NovoCure Limited, Q1 2022 Earnings Call, Apr 28, 2022
CI
04/28NOVOCURE : Q1 Earnings Snapshot
AQ
04/28NOVOCURE : Quarterly net revenues of $137.5 million with 80% gross margin - Form 8-K
PU
04/28Earnings Flash (NVCR) NOVOCURE Reports Q1 Loss $-0.04, vs. Street Est of $-0.19
MT
04/28Earnings Flash (NVCR) NOVOCURE Posts Q1 Revenue $137.5M, vs. Street Est of $134.3M
MT
04/28NOVOCURE LTD Management's Discussion and Analysis of Financial Condition and Results o..
AQ
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 552 M - -
Net income 2022 -62,6 M - -
Net Debt 2022 293 M - -
P/E ratio 2022 -123x
Yield 2022 -
Capitalization 7 498 M 7 498 M -
EV / Sales 2022 14,1x
EV / Sales 2023 13,1x
Nbr of Employees 1 167
Free-Float 86,5%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 71,69 $
Average target price 101,44 $
Spread / Average Target 41,5%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED-4.52%7 498
GETINGE AB-26.04%8 019
MASIMO CORPORATION-52.19%7 770
SHOCKWAVE MEDICAL, INC.-7.22%5 922
PENUMBRA, INC.-47.51%5 683
ASAHI INTECC CO., LTD.-16.55%4 330